Understanding Hormone Replacement Therapy: Benefits, Formulations, and Risks

Related service: Hormone Replacement Therapy

Menopausal hormone therapy is the most effective treatment for hot flashes and night sweats and also prevents bone loss while it is used. Whether it is appropriate depends on symptoms, age, time since menopause, uterine status, bleeding, cardiovascular and clot risk, breast history, migraine, liver disease, and patient preference. Estrogen may be oral or transdermal. A patient with a uterus generally needs adequate progestogen with systemic estrogen. Low-dose vaginal estrogen is a separate local treatment for vaginal and urinary symptoms.

Which Symptoms Respond Best

Systemic estrogen is highly effective for vasomotor symptoms and can improve sleep when night sweats cause awakenings. It may improve joint discomfort, mood, or perceived cognition for some patients, but it is not a universal treatment for fatigue, depression, weight gain, or brain fog. Those symptoms require evaluation for sleep disorders, thyroid disease, anemia, medication effects, and other causes.

Genitourinary syndrome of menopause causes dryness, burning, painful intercourse, urgency, and recurrent UTIs. When these are the only symptoms, low-dose vaginal estrogen is usually preferred because it targets local tissue with minimal systemic exposure. Systemic therapy may not provide adequate local relief, so both can sometimes be used.

Oral Versus Transdermal Estrogen

Oral estrogen passes through the liver before reaching systemic circulation and affects clotting proteins, triglycerides, and binding proteins. It may be convenient and appropriate for many healthy patients. Transdermal estradiol is delivered by patch, gel, or spray and avoids first-pass liver metabolism.

Observational evidence suggests transdermal estradiol and lower doses may carry less venous-thromboembolism and stroke risk than oral therapy. Transdermal treatment is often favored with migraine, elevated triglycerides, obesity, metabolic risk, or increased clot concern when systemic estrogen is otherwise appropriate. Adhesion, skin reaction, cost, and dosing frequency influence choice.

Why Progesterone Is Needed With a Uterus

Systemic estrogen stimulates the endometrium. Without adequate opposition, prolonged exposure increases hyperplasia and endometrial cancer risk. Micronized progesterone, synthetic progestins, or a suitable levonorgestrel IUD may be used depending on regimen, dose, route, bleeding goals, and evidence.

Continuous progesterone aims for eventual amenorrhea but can cause early spotting. Cyclic progesterone produces scheduled withdrawal bleeding. Micronized progesterone may be sedating and is often taken at bedtime. No progestogen regimen should be assumed adequate for every estrogen dose without reviewing established endometrial-protection data.

Who Has the Most Favorable Benefit-Risk Profile

For most healthy symptomatic women younger than 60 or within 10 years of menopause onset, major menopause societies conclude that benefits generally outweigh risks when treatment is individualized. Starting later than age 60 or more than 10 years after menopause carries a less favorable profile because baseline cardiovascular, stroke, clot, and dementia risks are higher.

Primary ovarian insufficiency and early menopause are different. In the absence of contraindication, hormone replacement is usually recommended until approximately the average age of natural menopause to protect bone and reduce consequences of early estrogen deficiency. This is replacement of prematurely lost hormones, not simply optional symptom treatment.

Understanding the WHI Numbers

The Women’s Health Initiative tested one specific older regimen: oral conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg in women whose average age was about 63. Per 10,000 women-years, that trial reported approximately 7 more coronary events, 8 more strokes, 10 more pulmonary emboli, and 8 more invasive breast cancers, with about 6 fewer colorectal cancers and 5 fewer hip fractures.

Those numbers should not be applied directly to every modern patient, dose, route, progestogen, or age. Younger participants had lower absolute event rates, transdermal estradiol has a different clot-risk profile in observational data, and estrogen-only therapy after hysterectomy had different breast outcomes. The WHI remains important but does not justify treating all hormone therapy as one exposure.

Breast, Clot, Stroke, and Heart Considerations

Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk that becomes more relevant with duration. Estrogen alone after hysterectomy did not show the same pattern in WHI and was associated with lower breast cancer incidence during extended follow-up. Personal and family history, prior biopsies, breast density, alcohol, obesity, and screening status all contribute to baseline risk.

Oral systemic therapy increases venous clot risk, especially with age, obesity, thrombophilia, immobility, and prior events. A history of unexplained clot, stroke, myocardial infarction, estrogen-dependent cancer, active liver disease, or unexplained vaginal bleeding may contraindicate systemic treatment or require specialist input. Hormone therapy is not started to prevent cardiovascular disease.

Bioidentical and Compounded Hormones

FDA-approved estradiol and micronized progesterone are bioidentical, meaning their molecular structures match endogenous hormones. Compounded products are not automatically safer or more natural. They can have variable potency, purity, absorption, and sterility and lack the standardized labeling and safety evidence of approved products.

Salivary hormone testing is not a reliable way to dose menopause therapy. Treatment is adjusted to symptom response, side effects, bleeding, and appropriate safety monitoring. Routine pursuit of a premenopausal laboratory number can lead to unnecessary supraphysiologic dosing.

Testosterone and Pellets

Systemic testosterone has evidence for hypoactive sexual desire disorder in appropriately assessed postmenopausal women, using doses that maintain female physiologic levels. It is not an established treatment for general fatigue, weight loss, or cognition. Acne, hair growth, scalp hair loss, voice change, clitoral enlargement, lipid effects, and excessive levels require monitoring.

Pellets cannot be removed easily once inserted and may produce prolonged or supraphysiologic exposure. They are not first-line in major menopause guidelines when titratable approved routes are available. Any pellet plan should include informed consent about evidence, monitoring, cost, and reversibility.

Follow-Up and Duration

Follow-up assesses symptom control, blood pressure, adverse effects, bleeding, adherence, and whether the route or dose remains appropriate. New or persistent bleeding requires evaluation. There is no universal rule to stop at age 60, 65, or after five years; continuation is individualized with periodic reassessment.

Frequently Asked Questions

Do I need progesterone if I had a hysterectomy?

Usually not for endometrial protection because the uterus is absent, although endometriosis or another special circumstance can change the plan.

Is a patch safer than a pill?

Transdermal estradiol likely has lower clot and possibly stroke risk than oral estrogen, but it is not risk-free and overall eligibility still matters.

Can hormone therapy help me lose weight?

It is not a weight-loss treatment. Improved sleep and symptom control may support healthier activity, but aging, muscle, nutrition, and metabolic factors remain important.

Do I need yearly hormone levels?

Usually not. Dosing is based mainly on symptoms, side effects, bleeding, and safety. Levels are useful in selected situations, especially testosterone treatment.

Can I continue hormone therapy after 65?

Some patients can after individualized reassessment. Persistent symptoms, dose, route, bone needs, and evolving breast, clot, cardiovascular, and cognitive risks should be reviewed.

Schedule a Consultation

The Bottom Line

Understanding Hormone Replacement Therapy is best approached with individualized assessment rather than a one-size-fits-all plan. A visit can clarify what evaluation or treatment fits your symptoms, history, and goals.

Schedule a Visit

Complete Healthcare offers individualized menopause and hormone care counseling for patients in Richland and the Tri-Cities. Call 509-392-6700 to schedule a menopause visit.

Complete Healthcare, Richland, WA

Richard Lorenzo, D.O.

Women’s Health and Wellness Care in Richland, WA